

## Dr. med. Pascal JUILLERAT, MD, MSc

### Kernkompetenzen

- **Spezialisierte Crohn und Colitis Sprechstunde**
- **Leitung der Betreuung der stationären Patienten mit chronisch entzündlichen Darmerkrankungen (CED)**
- **Leiter des Zentrums für klinische Forschung bei CED Patienten**
- **FMH Gastroenterologie und Hepatologie : Betreuung von gastroenterologischen und hepatologischen Patienten**
- **Master of Science in Epidemiology: Leitung Epidemiologische Studien.**

### Schulen, Studium, Diplome

1995 - 2000	Medizin Studium, Fakultät für Medizin, Lausanne Universität und Basel
Dez. 2000	Schweizer Medizin Diploma vom Lausanne Universität
Feb. 2008	Doktorarbeit: "Prevalence of Inflammatory Bowel Disease in the Canton of Vaud (Switzerland)", Fakultät für Medizin, Lausanne Universität
2009	FMH Gastroenterologie und Hepatologie (Foederatio Medicorum Helveticorum (Schweizerische Gesellschaft für Medizin)
2010	Master degree of Science (MSc) in Epidemiology, Harvard University, Boston
2011	Advanced Inflammatory Bowel Disease Clinical Fellowship, Massachusetts General Hospital, Harvard School of Medicine, Harvard University, Boston.

### Werdegang

#### Facharzt Ausbildung

2001 – 2002	Innere Medizin, Spital Nyon, Schweiz
2002 – 2003	Forschung, (Gastroenterologie) CHUV Lausanne, Schweiz
2003 – 2005	Innere Medizin, CHUV Lausanne, Schweiz
2005 – 2007	Gastroenterologie und Hepatologie, CHUV Lausanne, Schweiz
2007 – 2008	Gastroenterologie und Hepatologie, HUG Genf, Schweiz
2008 – 2009	Sozial und Präventiv Medizin und Gastroenterologie, CHUV Lausanne, Schweiz

## Forschung und klinische Weiterbildung

- 2009 – 2010      Master in Science in Epidemiology, Harvard School of Public Health, Boston
- 2009 – 2010      Research fellow Medicine/ Gastrointestinal Unit, Massachusetts General Hospital, (Profs Bruce E Sands and Joshua R Korzenik )
- 2010 – 2011      Advanced Clinical Fellow in Inflammatory Bowel Disease, MGH Crohn's and Colitis Center, Gastrointestinal Unit, Massachusetts General Hospital, Boston (Prof. Joshua R Korzenik)

## Facharzt Gastroenterologie

- Seit 2011          Gastroenterologie Oberarzt I, Universitätsklinik für Viszerale Chirurgie und Medizin, Inselspital, Universitätsspital Bern (Prof. Andrew Macpherson)

## Sprachen

- Deutsch          fließend
- Französisch    Muttersprache
- Englisch        fließend

## Mitgliedschaften

- Seit 2014          Executive Committee of the Swiss IBDnet ([www.ibdnet.ch](http://www.ibdnet.ch))
- Seit 2012          Executive Committee of the Swiss Inflammatory Bowel Disease Cohort Study
- 2011- 2013        International Editorial Advisory Board of the Journal of Crohn's and colitis
- Seit 2009          Swiss Gastroenterological Society (SSG-SGG)
- 2008 – 2011      Member of the American Gastroenterological Association (AGA)
- Seit 2007          Member of ECCO (European Crohn's Colitis Organization)
- Seit 2006          Scientific Committee of the Swiss Inflammatory Bowel Disease Cohort Study

## Grants

- Swiss National Science Foundation (PBLAP3—124341): "Comparison between Swiss and American Cohort Studies of Inflammatory Bowel Diseases Patients", 01.07.2009
- The Foundation for Clinical Research in IBD ([www.myIBD.org](http://www.myIBD.org)): "Proton-pump Inhibitors in Inflammatory Bowel Disease", 01.03.2010
- Ruth & Arthur Scherbarth Foundation: "Sensitivity To Anti-Tnfs Inhibition In Crohn's Disease And Ulcerative Colitis: The Saticc- Study ", 01.06.2012

## Vorlesungen

### Medizinische Fakultät Bern

- 4. Jahr Medizin „Kolonkarzinom“ (2011 -2012)
- 3. Jahr Medizin "Hemmung der Säuresekretion" (ab 2012)
- 6. Jahr Medizin „Seminar - Fallpräsentation: Crohn/Colitis" (ab 2013)
- 4. Jahr Medizin „Einführungskurs: Crohn/Colitis" (ab 2013)
- 6. Jahr Medizin „Veränderung der Stuhlgewohnheiten, Frischblutabgang ab ano" (ab 2014)
- Master of Science in Biomedical “Biological Therapies for IBD" (ab 2014)  
"Introduction to inflammatory bowel diseases (IBD)" (ab 2015)

## Regular Reviewer

- British Medical Journal
- American Journal of Epidemiology
- American Journal of Gastroenterology
- Inflammatory Bowel Disease
- Journal of Crohn's and colitis
- Alimentary Pharmacology & Therapeutics
- PLOs One
- Scandinavian Journal of Gastroenterology
- Digestive Liver Disease
- Digestion
- Colorectal Disease
- Swiss Medical Weekly
- European Journal of Gastroenterology & Hepatology
- Expert Review of Gastroenterology and Hepatology
- Expert Opinion on Drug Safety

## Book chapter

P. Juillerat and J. R. Korzenik,

Chapter: Novel NonBiologic Therapy for ulcerative colitis,

Book: Medical Therapy of Mucosal Ulcerative Colitis,

Editor: G. Lichtenstein, Springer Science & Business Media, Nov. 2014

ISBN 978-1-4939-1676-4

## Publications (Selection of 10)

h-index: 14 (based on Scopus and Web of Science citation report, Nov. 2014), and 62 citations [51 as author] in Pubmed.

10 original manuscript and 4 review articles as first author (18 and 20 as co- author), highest IF are 6.091 and 16.2, resp.

1. van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, Kolacek S, **Juillerat P**, Mulders AG, Pedersen N, Selinger C, Sebastian S, Sturm A, Zelinkova Z, Magro F; The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. European Crohn's and Colitis Organization. *J Crohns Colitis*. 2015 Feb;9(2):107-24. PMID: 25602023
2. **Juillerat P**, Sokol H, Froehlich F, Yajnik V, Beaugerie L, Lucci M, Burnand B, Macpherson AJ, Cosnes J, Korzenik JR. Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond : a multi-center international cohort . *Inflamm Bowel Dis* 2015;21:60–70. PMID: 25517594
3. **Juillerat P**, Wasan SK, Fowler SA, Friedman S, Pabby VK, Coukas JA, Barto AE, Pellish R, Germansky KA, Cheifetz AS, Korzenik JR, Farraye FA, Yajnik V. Efficacy and Safety of Natalizumab in Crohn's Disease Patients Treated at 6 Boston Academic Hospitals. *Inflamm Bowel Dis*. 2013;19(11):2457-2463. PMID:23962896
4. **Juillerat P**, Sebastian Schneeweiss, Francis E. Cook, Ashwin N. Ananthakrishnan, Helen Mogun, Joshua R. Korzenik. Gastric acid inhibiting medications may alter the course of inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics*, 2012; 36(3):239-47. PMID: 22670722
5. Ananthakrishnan AN, Hur C, **Juillerat P**, Joshua Korzenik JR. Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis. *Am J Gastroenterol*. 2011; 106 (11):2009-17. PMID:21788991
6. Wyler von Ballmoos M, Haring B, **Juillerat P**, Alkadhi H. Diagnostic Performance of Low Radiation Dose Coronary CT Angiography – Systematic Review and Meta-analysis. *Annals of internal Medicine*, 2011; 154 (6):413-420. PMID:21403076
7. **Juillerat P**, Pittet V, Vader JP, Burnand B, Gonvers JJ, Beglinger C, de Saussure P, Mottet C, Seibold F, Rogler G, Sagmeister M, Felley C, Michetti P, Froehlich F and the Swiss IBD Cohort Study Group. Infliximab for Crohn's disease in the Swiss IBD Cohort study: Clinical management and appropriateness. *Eur J Gastroenterol Hepatol*. 2010; 22(11):1352-7. PMID: 20964261
8. **Juillerat P**, Vader JP, Felley C, Pittet V, Gonvers JJ, Mottet C, Willem A. Bemelman WA, Lémann M, Öresland T, Michetti P, Froehlich F and the EPACT II Study Group. Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel - EPACT II. *Journal of Crohn's and Colitis*, 2009. 3(4): 241-9. PMID: 21172282
9. **Juillerat P**, Peytremann-Bridevaux I, Vader JP, Arditi C, Schusselé Fillietaz S, Dubois RW, Gonvers JJ, Froehlich F, Burnand B, Pittet V. Appropriateness of colonoscopy in Europe (EPAGE II). Presentation of methodology, general results, and analysis of complications. *Endoscopy*. 2009; 41 (3):240-6. PMID: 19280536
10. **Juillerat P**, Pittet V, Bulliard JL, Guessous I, Antonino A, Mottet C, Felley C, Vader JP, Michetti P. Prevalence of Inflammatory Bowel Disease in the Canton of Vaud (Switzerland): A population-based cohort study, *Journal of Crohn's and Colitis* 2008; 2 (2):131–141. PMID 21172203

[Publications on Pubmed.gov](#)